GLPG.AS
Latest Trade
68.86EURChange
--(--)Today's Range
-
--52 Week Range
-
216.10As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 68.86 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 12.16 |
Today's High | -- |
Today's Low | -- |
52 Week High | 216.10 |
52 Week Low | 64.52 |
Shares Out (MIL) | 65.41 |
Market Cap (MIL) | 4,526.49 |
Forward P/E | -15.47 |
Dividend (Yield %) | -- |
Galapagos Reports Primary Endpoint For Ongoing Filgotinib Manta, Manta-Ray Safety Studies
Galapagos Says Ziritaxestat Didn't Change Appetite For Risk - Conf Call
Galapagos NV Says FY Diluted Loss Per Share EUR 4.69
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
Industry
Biotechnology & Drugs
Executive Leadership
Onno van de Stolpe
Chairman of the Executive Committee, Chief Executive Officer, Executive Director
Raj B. Parekh
Non-Executive Chairman of the Board
Bart Filius
Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer
Piet Wigerinck
Member of the Executive Committee, Chief Scientific Officer
Michele Manto
Chief Commercial Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 8.54 |
Price To Book (MRQ) | 1.70 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 1.10 |
LT Debt To Equity (MRQ) | 0.86 |
Return on Investment (TTM) | -5.88 |
Return on Equity (TTM) | -5.28 |
Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis, the companies said on Wednesday.
Galapagos NV and partner Gilead Sciences Inc will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis, the companies said on Wednesday.
Gilead Sciences Inc said on Tuesday it had decided not to pursue the U.S. Food and Drug Administration's approval for its experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.
Peru's Navy on Friday was carefully watching a fleet of around 250 Chinese fishing vessels that had sailed just outside the Andean country's waters, angering the domestic fishing industry and sparking a Twitter war between Washington and Beijing.
Ecuador's navy said on Tuesday that Chinese fishing vessels have gradually left the area near the Galapagos Islands and are now operating in international waters off Peru, following months of fishing that spurred criticism from environmental groups.
* E-THERAPEUTICS PLC - COLLABORATION WITH GALAPAGOS TO DISCOVER THERAPEUTIC STRATEGIES FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS Source text for Eikon: Further company coverage:
* ANNOUNCED ON THURSDAY SHARE CAPITAL INCREASE THROUGH SUBSCRIPTION RIGHT EXERCISES
Gilead Sciences Inc <GILD.O> and partner Galapagos NV <GLPG.AS> said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients.
* GILEAD AND GALAPAGOS ANNOUNCE POSITIVE TOPLINE RESULTS OF PHASE 2B/3 TRIAL OF FILGOTINIB IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Gilead Sciences Inc and partner Galapagos NV said on Wednesday a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a mid-stage study testing it in ulcerative colitis patients.
* ANNOUNCED ON THURSDAY : FIRST THREE-MONTH 2020 FINANCIAL RESULTS
* GALAPAGOS CREATES NEW SUBSCRIPTION RIGHT PLANS Source text for Eikon: Further company coverage:
* SIGNS RESEARCH AND DEVELOPMENT COOPERATION DEAL WITH BELGIUM-BASED GALAPAGOS
* TODAY ANNOUNCED A COLLABORATION FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL MOLECULE DRUGS IN INFLAMMATION
* GALAPAGOS NV - FY GROUP REVENUES & OTHER INCOME OF EUR 896 MILLION, COMPARED TO EUR 318 MILLION IN 2018
* SAID ON MONDAY ISSUED 95,180 NEW ORDINARY SHARES ON NOV 25, FOR TOTAL CAPITAL INCREASE OF EUR 2.7 MLN
* ANNOUNCED ON THURSDAY AN ISSUE OF 301,745 NEW ORDINARY SHARES ON SEP 18, 2019, FOR TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 6.7 MLN
* GALAPAGOS-FILED APPLICATION TO INITIATE INSOLVENCY PROCEEDINGS WITH COMPETENT LOCAL COURT OF DÜSSELDORF DUE TO PENDING ILLIQUIDITY & OVER-INDEBTEDNESS
U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>, news that lifted Galapagos's shares more than 18% to an all-time high on Monday.
U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.